Increasing data on psychedelics’ safety and effectiveness may lead to more effective treatments for adult mental health problems, including depression, anxiety, and post-traumatic stress disorder. Although the FDA declined to approve MDMA-assisted therapy in August 2024, clinical research continues — with revised trial designs intended to address the agency’s methodological concerns.
The MDMA program developed a small team of psychedelic researchers. They had worked for years despite criticism, funding difficulties, and disapproval. Phase 2 and Phase 3 data suggest this approach may offer higher response rates and better patient compliance than standard PTSD treatments, though FDA approval was not granted in 2024.
What is MDMA?
MDMA is a synthetic entactogen (empathy-inducing substance), also known as 3,4-methylenedioxymethamphetamine. It is not a classic psychedelic, though it is sometimes grouped with psychedelics in a broader sense. This psychoactive substance is often known as ecstasy in recreational settings, but ecstasy and clinical MDMA are not the same thing. Pharmaceutical standards are followed in the production of MDMA for clinical use.
MDMA elevates serum oxytocin resulting in positive emotional cues. It affects a person’s spatial and perceptional distortions and increases the satisfaction of sensory experiences. MDMA enhances emotional empathy and self-awareness. The drug experience is pleasurable and lucid. While MDMA does carry a risk of misuse, clinical research has not found it to have the high addiction potential associated with substances like opioids or stimulants. The risk of psychological dependence exists but is considered moderate.
What is MDMA-assisted psychotherapy?
Administering MDMA in line with a doctor’s recommendation as a supplement for therapy sessions is known as MDMA-assisted psychotherapy. According to research, MDMA-assisted psychotherapy may enhance treatment efficacy for complex and treatment-resistant PTSD diagnosis and other forms of post traumatic stress disorder (severe PTSD).
MDMA-assisted psychotherapy session looks less like standard psychiatric medication and more like a high-level talk therapy session that needs specific attention and supervision. It incorporates a therapeutic partnership where one is expected to dive into the experience, learn from it, and then process, integrate, and share those experiences in the following days. Individual practitioners provide psychedelic therapy in accordance with their own procedures because there is no accepted technique of administration and practice. But there are a few things in common:
- Administering MDMA in a controlled, clinical dose
- Professional supervision throughout the experience
- Retaking the psychedelic dose with a one- to two-week gap between doses
The elements of “set” and “setting” are crucial during a psychedelic session. The set includes concepts like attitude and anticipation. The setting describes the session’s location and interaction with the therapist. It is important to feel at ease with both the therapist and the setting. The result suggests that in contrast to more conventional psychiatric drugs like antidepressants, which may make an individual feel better more automatically, the effect of MDMA-assisted psychotherapy comes from the person’s experience and conscious reflection.
Certification Program
The therapy Certification Program offers high-quality instruction and oversight to assist therapists in providing moral care in psychedelic assisted psychotherapy. The organizations take their responsibility to ensure participant safety and their function in encouraging ethical development for people who take part in clinical programs.
To uphold this commitment, the group created the MAPS Code of Ethics for Psychedelic Psychotherapy, which serves as a set of principles and rules for psychotherapy within the MAPS framework. Instead of attempting to impose a predetermined course or outcome on the participant’s emotional process, the therapists should have a client-centered orientation and should have completed enough inner work to feel comfortable following and supporting whatever course the participant’s emotional process takes.
Clinical trials
Midway through the 1980s, the USA outlawed MDMA, primarily due to its rising recreational usage, and research into its use as a therapeutic agent ended. With the publication of a paper in 2010, clinical research resumed. That was the start of Phase 2, so MDMA assisted psychotherapy trials continued. Clinical trials demonstrated significant reductions in PTSD symptoms. In 2017, the FDA designated MDMA-assisted therapy as a “breakthrough treatment.”
Phase 3 clinical trials were conducted as randomized, double-blind, controlled studies across multiple sites in the United States, Canada, and Israel. In August 2024, the FDA declined to approve MDMA-assisted therapy for PTSD, citing concerns about the trial methodology and requesting additional data. In April 2026, a U.S. executive order directed the FDA to issue priority review vouchers for psychedelic treatments with Breakthrough Therapy designation, aiming to shorten approval timelines from years to weeks. MDMA’s specific path still depends on the next trial and resubmission, but the regulatory window has meaningfully shifted.
MAPS has made available a visual representation of its research:
What could MDMA-assisted therapy be used for?
Researchers are investigating MDMA-assisted therapy as an addition to psychotherapy sessions for PTSD and other mental health conditions. Although the FDA declined approval in August 2024, clinical research continues to explore its potential for conditions such as:
Posttraumatic stress disorder
MDMA alters emotional processing and positively impacts social interaction. It fosters emotional connection. That is why MDMA may be more effective for treating PTSD than other diseases. A 2018 study found that octopuses given MDMA spent more time near other octopuses — an unexpected observation given that octopuses are typically solitary. Researchers noted this as consistent with MDMA’s serotonergic mechanism, though it cannot be directly translated to human social behavior.
In a therapeutic environment, PTSD victims open up and speak about their memories, reliving their traumas while doing so, and then experience a wave of self-compassion that enables them to let go of the past and go on. The therapist acts as a non-prescriptive guide throughout the therapeutic session and creates a safe environment.
MDMA-assisted couple therapy
Before MDMA was outlawed in the middle of the 1980s, couple therapy with MDMA was practiced. In several examples of MDMA-assisted therapy research, including those involving couples, Greer and Tolbert (1986, 1998) found that patients’ fears of emotional harm decreased, and their ability to communicate and reflect increased.
In a relational context, an MDMA session can facilitate meaningful interpersonal healing and growth. The pair is developing a model for future interactions that will help them communicate effectively, reflect together after stressful events, and navigate intense emotional experiences. This can assist model the experience for their partnership by developing an attitude of cultivating trust and openness to whatever occurs in the treatment process.
Individual MDMA-assisted psychotherapy could be used in depression treatment. Findings from dyadic interventions for specific diagnoses demonstrate improvement in both mental health outcomes (OCD, PTSD, depression), relationship satisfaction, and functioning for both partners.
Anxiety
MDMA is not an approved prescription drug. Anxiety, cannot be treated with it by prescription. However, MDMA is being looked into as a possible therapy for post-traumatic stress, depression, and anxiety. Although further research is required, the encouraging outcomes of trials involving MDMA to treat people with PTSD have prompted some researchers to hypothesize that MDMA might potentially be a useful adjunct to treat psychiatric disorders like:
- Depression
- Anxiety problems
- OCD-obsessive compulsive disorder
- Suicidality
- Diseases caused by drug addiction
Eating disorder
A randomized placebo-controlled study on adults with severe PTSD found that eating disorder symptoms were considerably reduced by MDMA-assisted therapy. Even when EDs are not present, people with PTSD frequently have low weight. When compared to therapy with a placebo, the effects of MDMA-assisted therapy dramatically improved Eating Disorder symptoms in individuals with severe PTSD.
Risks to consider
MDMA carries risks that extend beyond those with psychotic disorders. Known risks include cardiovascular effects (increased heart rate, blood pressure, and body temperature), serotonin syndrome when combined with other serotonergic drugs, and the possibility of adverse psychological reactions such as panic, anxiety, and paranoid symptoms. Effects can vary according to dosage, individual physiology, and environment. MDMA is contraindicated in individuals with cardiovascular conditions, liver problems, or those taking MAO inhibitors or SSRIs.
How to get started?
You can be part of the research trial if you’re curious about trying psychedelic therapy. The National Institute of Health can look for clinical trials accepting volunteers (NIH). Research and trials that accept volunteers may also be sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the John Hopkins Center for Psychedelic and Consciousness Research.
MDMA should only be used under medical supervision. Unsupervised use carries serious risks: acute MDMA intoxication can be life-threatening, street MDMA is frequently adulterated, and there is no integration support outside a clinical framework. In clinical trials, participants receive a verified pharmaceutical dose, continuous monitoring, and trained therapist support throughout.
Vivien Freeflow
· Updated
